NEW YORK – Scipher Medicine on Wednesday said it would partner with Atropos Health to expand the company's immunology dataset.
Atropos corrals data from millions of de-identified patient records on its Atropos Evidence Network, which it uses in tools designed to inform clinical decision-making. Scipher, which aims to support drug development with artificial intelligence (AI) and network biology, has one of the largest datasets on rheumatoid arthritis (RA), including genomic, biobank, and electronic medical record data.
As part of this collaboration, Waltham, Massachusetts-based Scipher will add patient data derived from its PrismRA blood test to Atropos' immunology multimodal network, which is part of the Atropos Evidence Network. PrismRA analyzes RA patients' molecular data to identify those unlikely to respond to tumor necrosis factor inhibitors.
Data from the Atropos Evidence Network fuels various software tools, including ChatRWD, a ChatGPT-style AI chatbot that Atropos developed. Physicians and researchers can ask ChatRWD medical questions that the software program answers by pulling and analyzing data from the Atropos Evidence Network.
"By combining Scipher's unique RA data assets with Atropos Health's cutting-edge AI evidence generation tools, like ChatRWD, we can provide clinicians with powerful tools to make more informed treatment decisions and deliver personalized care," Scipher CEO Reg Seeto said in a statement.
Atropos Cofounder and CEO Brigham Hyde in a statement added, "Scipher's PrismRA data will ultimately lead to more opportunities to generate rapid evidence with ChatRWD and more rapidly close the evidence gap in medicine."